pioglitazone / metformin

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Glubrava has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 18/10/2022

Authorisation details

Product details
Agency product number
Active substance
  • metformin hydrochloride
  • pioglitazone hydrochloride
International non-proprietary name (INN) or common name
  • pioglitazone
  • metformin
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Takeda Pharma A/S
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Delta Park 45
2665 Vallensbaek Strand

Product information

04/02/2021 Glubrava - EMEA/H/C/000893 - WS/1979/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Glubrava is indicated as second line treatment of type-2-diabetes-mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.

After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
6 ratings
9 ratings
8 ratings
5 ratings